ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 978,51
0,55%
Dow Jones
38 111,48
-0,86%
DAX
18 496,79
0,12%
Brent Oil
81,95
-1,71%
Bitcoin
68 326,90
1,10%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) Actualités

MRTX

Mirati Therapeutics (MRTX)

Mirati Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MRTX
DateHeureSourceTitreSymboleSociété
14/02/202420h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRTXMirati Therapeutics Inc
02/02/202422h05Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MRTXMirati Therapeutics Inc
25/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRTXMirati Therapeutics Inc
24/01/202402h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415h31Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415h30Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202415h28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202414h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRTXMirati Therapeutics Inc
10/01/202414h00PR Newswire (US)European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
27/12/202322h04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
06/12/202314h29Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MRTXMirati Therapeutics Inc
10/11/202313h30PR Newswire (US)Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedureNASDAQ:MRTXMirati Therapeutics Inc
06/11/202314h00PR Newswire (US)Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:MRTXMirati Therapeutics Inc
06/11/202313h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRTXMirati Therapeutics Inc
03/11/202322h19PR Newswire (US)Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
02/11/202312h30Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
02/11/202312h30GlobeNewswire Inc.Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNASDAQ:MRTXMirati Therapeutics Inc
23/10/202323h31Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
17/10/202322h00PR Newswire (US)Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)NASDAQ:MRTXMirati Therapeutics Inc
09/10/202316h30Dow Jones NewsTrending: Bristol Myers Squibb Buying Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
09/10/202313h33IH Market NewsMonday’s Wall Street Highlights: Exxon Mobil, Bristol-Myers, Disney, Lockheed Martin, and moreNASDAQ:MRTXMirati Therapeutics Inc
09/10/202312h26Dow Jones NewsMirati Shares Slip Premarket on Bristol Myers TakeoverNASDAQ:MRTXMirati Therapeutics Inc
09/10/202301h21KR Market News브리스톨-마이어스 스퀴브, 48억 달러에 미라티 인수NASDAQ:MRTXMirati Therapeutics Inc
09/10/202300h02Business WireBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202308h56Dow Jones NewsSanofi Considering Acquisition of Mirati Therapeutics, Bloomberg ReportsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202302h33KR Market News사노피, 항암제 제조사 미라티 인수 검토 – 외신NASDAQ:MRTXMirati Therapeutics Inc
05/10/202322h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRTXMirati Therapeutics Inc
02/10/202322h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRTXMirati Therapeutics Inc
27/09/202322h30PR Newswire (US)Mirati To Present Updated Clinical Data at ESMO Congress 2023NASDAQ:MRTXMirati Therapeutics Inc
10/09/202304h35PR Newswire (US)Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung CancerNASDAQ:MRTXMirati Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRTX

Dernières Valeurs Consultées

NYSE
EICC
Eagle Point Income
COIN
MANOUSD
LSE
76WG
Investec Bnk 23
BIT
F18335
Vontobel Financial Produ...
USOTC
DONFF
LSE
94GG
Investec Bnk 23
BIT
F06345
Vontobel Financial Produ...
USOTC
ARPTF
Airport City (PK)
USOTC
GXUSF
Guardian Exploration (QB)
ASX
PGDNA
Peregrine Gold
EU
CACM
Amundi CAC MID 60 UCITS ...
LSE
82ZL
Investec Bnk 23
HUOB
REEFETH
Reef.finance
LSE
93RT
Investec Bnk 23
COIN
SNXGBP
Synthetix Network Token
BIT
F15426
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés